Revised SPC: Bendamustine hydrochloride Accord 2.5 mg/ ml Powder for concentrate for solution for infusion

SPC updated with information on cases of progressive multifocal leukoencephalopathy following use of bendamustine mainly in combination with rituximab or obinutuzumab. Increased risk for non-melanoma skin cancers also added - periodic skin examination recommended for all patients

Source:

electronic Medicines compendium